Emergent Biosolutions Inc. (NYSE:EBS) Receives Average Recommendation of “Hold” from Analysts

Emergent Biosolutions Inc. (NYSE:EBS) has received an average rating of “Hold” from the five ratings firms that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $10.00.

A number of research analysts recently issued reports on the stock. UBS Group reissued a “buy” rating on shares of Emergent Biosolutions in a research note on Tuesday, June 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Emergent Biosolutions in a research note on Friday, August 7th. Benchmark reiterated a “buy” rating on shares of Emergent Biosolutions in a research report on Tuesday, June 2nd. Zacks Research raised Emergent Biosolutions to a “hold” rating in a research note on Tuesday, August 11th. Finally, HC Wainwright cut their price objective on Emergent Biosolutions from $12.00 to $10.00 and set a “buy” rating on the stock in a report on Monday, August 10th.

Emergent Biosolutions Price Performance

Shares of EBS opened at $4.58 on Friday. The company’s fifty day simple moving average is $7.44 and its 200 day simple moving average is $8.52. Emergent Biosolutions has a 1-year low of $4.36 and a 1-year high of $14.06. The company has a market cap of $235.09 million, a price-to-earnings ratio of -1.29 and a beta of 2.35. The company has a current ratio of 5.42, a quick ratio of 2.95 and a debt-to-equity ratio of 1.70.

Emergent Biosolutions (NYSE:EBS) last posted its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.68. Emergent Biosolutions had a negative net margin of 22.95% and a positive return on equity of 16.35%. The firm had revenue of $234.30 million during the quarter, compared to the consensus estimate of $177.50 million. On average, research analysts forecast that Emergent Biosolutions will post -4.63 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Emergent Biosolutions news, SVP Paul Anthony Williams sold 3,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $8.40, for a total transaction of $25,200.00. Following the sale, the senior vice president directly owned 159,098 shares of the company’s stock, valued at $1,336,423.20. The trade was a 1.85% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.00% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Legal & General Group Plc bought a new stake in shares of Emergent Biosolutions during the 2nd quarter valued at about $31,000. Torren Management LLC bought a new stake in shares of Emergent Biosolutions in the 4th quarter valued at $37,000. CANADA LIFE ASSURANCE Co bought a new stake in shares of Emergent Biosolutions in the 4th quarter valued at $45,000. Raymond James Financial Inc. acquired a new position in shares of Emergent Biosolutions during the 2nd quarter valued at $53,000. Finally, Farther Finance Advisors LLC lifted its position in shares of Emergent Biosolutions by 361.3% during the 4th quarter. Farther Finance Advisors LLC now owns 6,163 shares of the biopharmaceutical company’s stock valued at $76,000 after acquiring an additional 4,827 shares during the period. 78.40% of the stock is owned by institutional investors and hedge funds.

About Emergent Biosolutions

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.